US · Healthcare · Biotechnology
EPS came in at -0.02 against a street estimate of -0.01 — a miss of 100.0%.
Analysts rate Immunocore Holdings Ltd a buy (13 buy, 3 hold, 1 sell out of 17) with an average price target of $62.50.
| Fund | Stake |
|---|---|
| Wellington Management Company LLP | 11.11% |
| RTW INVESTMENTS, LLC | 9.46% |
| FMR Inc | 9.38% |
| PRIMECAP Management Company | 7.06% |
| Bellevue Group AG | 5.43% |
| Vestal Point Capital LP | 5.37% |
| TANG CAPITAL MANAGEMENT LLC | 5.14% |
| T. Rowe Price Investment Management,Inc. | 3.67% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 IMMUNOCORE HOLDINGS PLC – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Revenue (6 months ended June 30, 2026): $222.6 million vs. $191.8 million (20 | 2026-08-06 |
| Results announced · Q3 2026 IMMUNOCORE HOLDINGS PLC – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • KIMMTRAK net revenues: $115.9 million in Q2 2026, up 18% year-over-year from | 2026-08-06 |
| Shareholder vote results · Q2 2026 IMMUNOCORE HOLDINGS PLC – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting held May 27, 2026 • Total shareholder votes cast: approximately | 2026-05-27 |
| Quarterly report · Q1 2026 IMMUNOCORE HOLDINGS PLC – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $106.7 million (up 13.5% from $93.9 million in Q1 2025) - Unite | 2026-05-06 |
| Results announced · Q2 2026 IMMUNOCORE Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • KIMMTRAK net sales: $106.7 million in Q1 2026, up 13.6% year-over-year from $93.9 mi | 2026-05-06 |
| Proxy statement · Q2 2026 IMMUNOCORE HOLDINGS PLC – PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Resolution 1: Re-appoint Siddharth Kaul as director — Board | 2026-04-16 |
| Annual report FY2025 IMMUNOCORE HOLDINGS PLC – FORM 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): Approximately | 2026-02-25 |
| Results announced · Q1 2026 IMMUNOCORE HOLDINGS PLC - FINANCIAL SUMMARY HEADLINE NUMBERS • KIMMTRAK (tebentafusp) Q4 2025 net sales: $104.5 million (up 24% vs Q4 2024's $84.1 m | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immunocore Holdings Ltd — free to start.
Google PlayApp StoreData updated 2026-09-18.